opted for a single primary endpoint, that of Schirmer's test, in the Phase 3 TRANQUILITY-2 trial of its 0.25% reproxalap ophthalmic solution (reproxalap) for dry eye disease, reported BTIG analyst, Dr. Thomas Shrader, in a May 24 research note. Aldeyra is developing treatments for various immune-mediated diseases.
Shrader also noted Aldeyra is trading at about US$2.85 per share, but BTIG's target price on it is multiples of that, at US$29 per share. This difference implies a significant potential return for investors.
Aldeyra "represents an attractive and derisked investment opportunity ahead of its first new drug application filings around mid-2022," wrote Shrader.
For BTIG, which rates the U.S. biopharma Buy, Aldeyra "represents an attractive and derisked investment opportunity ahead of its first new drug application filings around mid-2022," wrote Shrader.
As for Aldeyra's endpoint decision for TRANQUILITY-2, the options it did not choose are:
1) two endpoints, Schirmer's test, and eye redness
2) consideration of redness only if Schirmer's is positive.
Prior clinical trial results likely influenced Aldeyra, noted Shrader. Specifically, Schirmer's was highly positive in TRANQUILITY-1, but the redness was not. Redness was only positive in the smaller Phase 2 trial.
"Redness is important to patients, but the recent computer-aided redness evaluation of TRANQUILITY-1 is likely publishable and then can be distributed to physicians," Shrader noted.
The seeming motivation behind the company's single endpoint move, Shrader purported, is to eliminate the potential for an alpha split and achieve a "label that physicians are used to (Schirmer's) and also with a secondary publication package that suggests the drug could do more."
In other news, regarding Aldeyra's systemic RASP, or reactive aldehydes, modulator ADX-629, recently announced systemic data "looked good to us and better than the intended exercise in signal seeking," reported Shrader. Psoriasis was the indication that showed the most promising results over asthma and over COVID-19. Data suggested most psoriatic patients benefitted.
Upcoming catalysts for Aldeyra, Shrader pointed out, include topline data from TRANQUILITY-2 in Q2/22 and new drug application filing for reproxalap in mid-2022.
|Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter.||Subscribe|
1) Doresa Banning wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with: None Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities ofcompanies mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
Disclosures For BTIG LLC, Aldeyra TherapeuticsMay 24, 2022
Analyst Certification: I, Thomas Shrader, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
I, Sung Jun Hong, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
Company–Specific Regulatory Disclosures: BTIG LLC expects to receive or intends to seek compensation for investment banking services in the next 3 months from: Aldeyra Therapeutics (ALDX).
General Disclosures: Research reports produced by BTIG LLC (“BTIG”) are published for and intended to be distributed solely to BTIG institutional and corporate clients. Recipients of BTIG reports will not be considered clients of BTIG solely because they may have received such BTIG report.
To the extent recipient accesses BTIG research, whether on a BTIG research website or through a third-party platform, BTIG is able to search, filter, download and review information on the readership of BTIG’sresearch, including the specific research consumed and the name, company name, email address and, in certain circumstances, the location of the individual who accessed the research (the “Readership Information”). Recipient consents to BTIG’s receipt of the Readership Information, including receipt of that information from a third party.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues. BTIG reports are based on public information and BTIG considers the same to be reliable, comprehensive information, but makes no representation or warranty that the reports are accurate or complete. BTIG opinions and information provided in this report are as of the date of the report and may change without notice. An issuer may be classified as “Under Review” or “Research Restricted”. In these cases, investors should consider any previous investment recommendation and/or rating to a subject company/issuer to no longer be current and should not be relied upon nor considered a solicitation.
its affiliates not involved in the preparation of this research report may have investments in securities or derivatives of securities of companies mentioned in this report that are inconsistent with the views discussed in this report. Investors in securities products bear certain risks in conjunction with those investments. The value of, and income from, any investments may vary because of changes in interest rates or foreign exchange rates, securities prices or market indexes, operational or financial conditions of companies or other factors within or beyond the companies’ control. Recipient of the research reports should be aware that investments in securities may pose significant risks due to the inherent uncertainty associated with relying on forecasts of various factors that can affect the earnings, cash flow and overall valuation of a company.
Any investment in securitiesshould be undertaken only upon consideration of issuesrelating to the recipient’s overall investment portfolio and objectives (such as diversification by asset class, industry or company) as well as time horizon and liquidity needs. Further, past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. There may be time limitations on the exercise of options or other rights in any securities transactions.
Investing in foreign markets and securities, including ADRs, is subject to additional risks such as currency fluctuation, limited information, political instability, economic risk, and the potential for illiquid markets. Investing in emerging markets may accentuate these risks. Non-U.S. reporting issuers of foreign securities, however, may not make regular or complete public disclosure relating to their financial condition or the securities that they issue.
BTIG is a U.S. broker-dealer and member of FINRA and SIPC.